Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Kennedy Krieger Institute
mi
from
Baltimore, MD
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Kennedy Krieger Institute
mi
from
Baltimore, MD
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Umass Memorial Medical Center
mi
from
Worcester, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Umass Memorial Medical Center
mi
from
Worcester, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Univeristy of Missouri-Kansas City
mi
from
Kansas City, MO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Univeristy of Missouri-Kansas City
mi
from
Kansas City, MO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Seaver Autism Center, Mount Sinai Medical Center
mi
from
New York, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Seaver Autism Center, Mount Sinai Medical Center
mi
from
New York, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
New York State Institute for Basic Research in Dev. Disabilities
mi
from
Staten Island, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
New York State Institute for Basic Research in Dev. Disabilities
mi
from
Staten Island, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
University of North Carolina Hospital
mi
from
Chapel Hill, NC
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital
mi
from
Chapel Hill, NC
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital of Denver
mi
from
Denver, CO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital of Denver
mi
from
Denver, CO
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Cutting Edge Research
mi
from
Oklahoma City, OK
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Cutting Edge Research
mi
from
Oklahoma City, OK
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Summit Research Network
mi
from
Portland, OR
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Summit Research Network
mi
from
Portland, OR
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Suburban Research Associates
mi
from
Media, PA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Suburban Research Associates
mi
from
Media, PA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Vanderbilt University Medical Center
mi
from
Nashville, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
mi
from
Nashville, TN
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Red Oak Psychiatry Associates, P.A.
mi
from
Houston, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Red Oak Psychiatry Associates, P.A.
mi
from
Houston, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Road Runner Research
mi
from
San Antonio, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Road Runner Research
mi
from
San Antonio, TX
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Stress Reduction in Middle Eastern Refugees
Stress Reduction in Middle Eastern Refugees
Status: Archived
Wayne State University
mi
from
Detroit, MI
Stress Reduction in Middle Eastern Refugees
Stress Reduction in Middle Eastern Refugees
Status: Archived
Updated: 1/1/1970
Wayne State University
mi
from
Detroit, MI
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Clinical Innovations, Inc.
mi
from
Santa Ana, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Clinical Innovations, Inc.
mi
from
Santa Ana, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Clinical Innovations Inc.
mi
from
Riverside, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Clinical Innovations Inc.
mi
from
Riverside, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Sharp Memorial Hospital
mi
from
San Diego, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Sharp Memorial Hospital
mi
from
San Diego, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Artemis Institiute for Clinical Research
mi
from
San Diego, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Artemis Institiute for Clinical Research
mi
from
San Diego, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Coloado Clinical Trials Inc.
mi
from
Highlands Ranch, CO
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Coloado Clinical Trials Inc.
mi
from
Highlands Ranch, CO
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Accurate Clinical Trials
mi
from
Kissimmee, FL
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Accurate Clinical Trials
mi
from
Kissimmee, FL
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Northwest Behavioral Research Center
mi
from
Roswell, GA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Northwest Behavioral Research Center
mi
from
Roswell, GA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Precise Research Centers
mi
from
Flowood, MS
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Precise Research Centers
mi
from
Flowood, MS
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Medical & Behavioral Health Research
mi
from
New York, NY
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Medical & Behavioral Health Research
mi
from
New York, NY
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Village Clinical Research Inc.
mi
from
New York, NY
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Village Clinical Research Inc.
mi
from
New York, NY
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Zarzar Psychiatric Associates, PLLC
mi
from
Raleigh, NC
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Zarzar Psychiatric Associates, PLLC
mi
from
Raleigh, NC
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Summit Research Network (Oregon) Inc.
mi
from
Portland, OR
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Summit Research Network (Oregon) Inc.
mi
from
Portland, OR
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Lehigh Valley Hospital Mental Health Clinic
mi
from
Allentown, PA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Lehigh Valley Hospital Mental Health Clinic
mi
from
Allentown, PA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Clinical Neuroscience Solution, Inc.
mi
from
Jacksonville, FL
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Clinical Neuroscience Solution, Inc.
mi
from
Jacksonville, FL
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Pillar Clinical Research, LLC
mi
from
Dallas, TX
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
FutureSearch Clinical Trials, LP
mi
from
Dallas, TX
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
FutureSearch Clinical Trials, LP
mi
from
Dallas, TX
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
mi
from
San Antonio, TX
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
mi
from
San Antonio, TX
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depresstion
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status: Archived
Updated: 1/1/1970
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Behavioral Incentives to Increase Exercise in Cocaine Dependent Women
Using Behavioral Incentives to Promote Exercise Compliance in Cocaine Dependent Women
Status: Archived
Rubicon, Inc.
mi
from
Richmond, VA
Behavioral Incentives to Increase Exercise in Cocaine Dependent Women
Using Behavioral Incentives to Promote Exercise Compliance in Cocaine Dependent Women
Status: Archived
Updated: 1/1/1970
Rubicon, Inc.
mi
from
Richmond, VA
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication
Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication
Status: Archived
Penn Center for Women's Behavioral Wellness, University of Pennsylvania
mi
from
Philadelphia, PA
Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication
Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication
Status: Archived
Updated: 1/1/1970
Penn Center for Women's Behavioral Wellness, University of Pennsylvania
mi
from
Philadelphia, PA
Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication
Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication
Status: Archived
University of Pennsylvania, Pennsylvania Hospital Department of Neurology , 330 South 9Th Street
mi
from
Philadelphia, PA
Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication
Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication
Status: Archived
Updated: 1/1/1970
University of Pennsylvania, Pennsylvania Hospital Department of Neurology , 330 South 9Th Street
mi
from
Philadelphia, PA
Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication
Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication
Status: Archived
Penn OB/GYN Associates
mi
from
Philadelphia, PA
Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication
Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication
Status: Archived
Updated: 1/1/1970
Penn OB/GYN Associates
mi
from
Philadelphia, PA
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Tri Valley Urology
mi
from
Murrieta, CA
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Updated: 1/1/1970
Tri Valley Urology
mi
from
Murrieta, CA
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Urology Specialists, LLC
mi
from
Hialeah, FL
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Updated: 1/1/1970
Urology Specialists, LLC
mi
from
Hialeah, FL
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Rosemark Women Care Specialists
mi
from
Idaho Falls, ID
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Updated: 1/1/1970
Rosemark Women Care Specialists
mi
from
Idaho Falls, ID
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Female Pelvic Medicine & Urogynecology Institute of Michigan
mi
from
Grand Rapids, MI
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Updated: 1/1/1970
Female Pelvic Medicine & Urogynecology Institute of Michigan
mi
from
Grand Rapids, MI
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Bellevue ObGyn
mi
from
Bellevue, NE
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Updated: 1/1/1970
Bellevue ObGyn
mi
from
Bellevue, NE
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Delaware Valley Urology
mi
from
Franklin Twp, NJ
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Updated: 1/1/1970
Delaware Valley Urology
mi
from
Franklin Twp, NJ
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Piedmont Urology
mi
from
Gastonia, NC
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
The Altis Single Incision Sling System for Female Stress Urinary Incontinence Study
Status: Archived
Updated: 1/1/1970
Piedmont Urology
mi
from
Gastonia, NC